An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab and Nivolumab Combination Therapy in Virus-associated Tumors
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Various Advanced Cancer
Age: Between 18 - 80 Years
Gender: Male or Female
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required